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Dawn M Meyer1*, Jo-Ann Eastwood2, M Peggy Compton3, Karen Gylys2 and Justin A Zivin4Abstract
Background: Biologic sex can influence response to pharmacologic therapy. The purpose of this proof-of-concept
study was to evaluate the medicating effects of estrogen in the efficacy of acute antiplatelet loading therapy on
stroke outcome in the rabbit small clot embolic model.
Methods: Female and male (20/group) New Zealand White rabbits were embolized to produce embolic stroke by
injecting small blood clots into the middle cerebral artery via an internal carotid artery catheter. Two hours after
embolization, rabbits were treated with standard dose antiplatelet loading (aspirin 10 mg/kg plus clopidogrel
10 mg/kg). Primary outcome measures were platelet inhibition, behavioral outcome P50 (the weight of microclots
(mg) that produces neurologic dysfunction in 50% of a group of animals), and effect of endogenous estrogen on
outcome.
Results: For the first time in a non-rodent model of stroke, it was found that higher endogenous estrogen levels
resulted in significantly better behavioral outcome in female subjects (rs −0.70, p < 0.011). Platelet inhibition in
response to collagen, arachidonic acid, and adenosine diphosphate (ADP) was not significantly different in females
with higher vs. lower estrogen levels.
Conclusions: Behavioral outcomes are improved with females with higher endogenous estrogen levels treated
with standard dose antiplatelet loading. This is the first non-rodent study to demonstrate that higher endogenous
estrogen levels in female rabbits appear to be neuroprotective in ischemic stroke. This research supports the further
study of the effect of endogenous estrogen levels on outcome with standard dose antiplatelet loading in stroke
patients not eligible for revascularization therapies.
Keywords: Acute stroke, Stroke model, Antiplatelet, AspirinBackground
Women experience 55,000 more strokes annually than
men, are 30% less likely to receive recombinant tissue
plasminogen activator (rt-PA), and have poorer outcomes
when not acutely treated [1-4]. In addition, biologic sex
may mediate response to pharmacotherapies [5]. Molecu-
lar, animal, and clinical studies have clearly demonstrated
that biologic sex and endogenous sex steroids influence
stroke outcome [6]. Estrogen appears to provide neuro-
protection, with molecular, histological, and behavioral
outcomes being superior in infarcted pre-menopausal
females compared to both age-matched male and post-
menopausal or ovarectomized female subjects [7,8]. The* Correspondence: dmmeyer@ucsd.edu
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Diego, CA 92103-8466, USA
Full list of author information is available at the end of the article
© 2014 Meyer et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.role of endogenous estrogen and sex-specific responses
must be considered when developing new treatment strat-
egies to ensure that women receive efficacious treatment.
The purpose of this study was to evaluate the efficacy of
antiplatelet loading and the effects of endogenous estro-
gen on stroke outcome in female subjects in the rabbit
small clot embolic model (RSCEM). Previous dose escalat-
ing work in exclusively male rabbits in this model found
that acute antiplatelet loading with aspirin 10 mg/kg plus
10 mg/kg clopidogrel had the most significant benefit on
stroke outcome in the RSCEM [9]. Using the male group
from the previous work, this examined the mediating
effects of endogenous estrogen on stroke outcome with
standard dose antiplatelet loading (aspirin 10 mg/kg plus
10 mg/kg clopidogrel) on the primary outcomes of (1)
inhibition of platelet aggregation and (2) the relationshiptd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The RSCEM clinical rating scale
Observation
Reaction to embolization __Mild (nystagmus, withdrawal)
__Moderate (kicking)
__Severe (rolling, vocalization)
__Death
RSCEM rating __Normal (score = 0)
__Abnormal (score = 1)
Place a check next to the abnormal
behavior exhibited:
__Ataxia
__Leaning
__Circling
__Lethargy
__Nystagmus
__Loss of balance
__Loss of limb or facial sensation
__Paraplegia
__Death
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come in female animals.
Methods
Design and sample
This was a blinded study of the mediating effects of
endogenous estrogen in acute antiplatelet loading in the
RSCEM. Animals (20 females, 2–4 kg, 1 year old, New
Zealand White rabbits) were purchased from Rabbit
Source, Ramona, CA, USA. Rabbits were supplied food
(alfalfa cubes) and water ad libitum while under quaran-
tine in an enriched environment for at least 3 days be-
fore experimental use. The University of California Los
Angeles and Veterans Administration San Diego Health
System (VASDHS) Institutional Animal Care and Use
Committees (IACUC) approved the surgical and treat-
ment procedures used in this study (Modification #5
Protocol #07-043).
Procedures
All surgical, embolization, and histological procedures
were done based on the techniques of Zivin and Lapchak
[10-12]. The primary investigator unblinded to sex was
responsible for administering the stroke and treatment;
trained laboratory technicians blinded to sex and treat-
ment assessed the primary outcomes. Care was used
throughout the study to minimize pain and discomfort.
Per the IACUC approved protocol, rabbits were eutha-
nized if they showed extreme discomfort or were unable
to reach food or water.
Surgical procedures
Surgery was done in a controlled environment (22.8°C–
23.2°C), and all procedures were based on the tech-
niques of Zivin and Lapchak [10-12]. The RSCEM has
been utilized successfully in stroke research as it has
been used to test pharmacologic interventions such as
recombinant tissue plasminogen activator (rt-PA), NXY-
059, tenecteplase (TNK), and microplasmin [13-16]. The
rabbit remained conscious during clot administration
and treatment to more accurately mimic the human is-
chemic stroke condition. In addition, a validated clinical
rating score for RSCEM outcomes has been developed,
allowing researchers to quantify neurologic behavioral
responses in the model (Table 1) which has been shown
to have a <5% inter-rater variability providing a consist-
ent and easy measurement of clinical outcome [11].
A catheter is surgically implanted for injection of the
small clot. Rabbits were anesthetized with isoflourane (5%
induction, 3% maintenance) by face mask, the bifurcation
of the right carotid artery was exposed, and the external
carotid was ligated just distal to the bifurcation. A catheter
was inserted into the common carotid artery and advanced
to the internal carotid artery, secured with ligatures, andthe distal end left accessible outside the neck. The rabbits
were allowed to recover from anesthesia for a minimum of
2 h until they were awake and behaving normally as
evidenced by no identified persistent behaviors from the
RSCEM behavior scale prior to embolization (Table 1).
Preparation and administration of small clot embolism
Blood drawn from a donor rabbit was allowed to clot at
37°C and suspended in Dulbecco's phosphate buffered sa-
line (PBS) solution containing 0.1% bovine serum albumin
and emulsified with a Polytron small particle cutter (Kine-
matica GmbH, Kriens-Luzern, Sweden). Clots were sized
by sequential filtration through a 240-μm2 screen and a
105-μm2 nylon net; those retained were washed with PBS
and allowed to settle. This supernatant was then removed
and the clot particles labeled with tracer quantities of
15-μm radiolabeled microspheres (cobalt-57) to enable
quantification of clot weight after sacrifice. PBS solution
was then added to the clot particles so that clot particles
were suspended in 1 ml, which was drawn into a syringe
for administration.
Clot particles were rapidly administered through the
intra-arterial injection catheter, and the system was
flushed with normal saline ensuring that no air bubbles
were present that may cause air embolism. Animals that
died or were euthanized after embolization and treat-
ment were included in the study.
Drug administration
Animals were treated with a standard loading dose of anti-
platelets (aspirin 10 mg/kg plus 10 mg/kg clopidogrel) at
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sistent with the time at which rt-PA administration is no
longer feasible [17]. Medication was administered as an
intravenous (IV) injection into an ear vein with reconsti-
tuted acetylsalicylic acid (ASA) plus clopidogrel no sooner
than 5 min after reconstitution. Powdered drug was
obtained from Sigma-Aldrich (St. Louis, MO, USA) and
reconstituted in vehicle (Cavitron, Fisher Scientific,
Pittsburgh, PA, USA) per manufacturer's instructions
and diluted to a cubic centimeter volume. The per
kilogram doses of drugs reflect standard antiplatelet
doses in clinical practice [ASA 325 mg (10 mg/kg);
clopidogrel 300 mg (10 mg/kg)] [18,19].
Outcome measures
Platelet aggregation
Blood was collected at pre-stroke baseline, 3 h, 6 h, and
24 h by puncture of an ear vein into a 3.8% trisodium
citrate solution (1–2 cm3). Platelet aggregation was tested
via optical, whole blood single-channel Chrono-log aggreg-
ometer [20]. Responses to adenosine diphosphate (ADP),
arachidonic acid (AA), and collagen-induced aggregations
(concentrations, 2.5 μM, 250 μM, and 12 μg/ml, respect-
ively) were assessed. Platelet aggregation was recorded in
regard to the change of impedance (Ω) and was reported as
the percent decrease from baseline aggregation. The plate-
let aggregation measurements in whole blood samples will
be examined by an impedance aggregometer (Model 590,
Chrono-log Corporation, Havertown, PA, USA) using the
AggroLink software package. The system detects the
change of electrical impedance due to the adhesion and
aggregation of platelets on the electrode's surface in the test
cuvette. Impedance aggregometry testing was performed
between 60 and 180 min after drawing blood. The mea-
surements were carried out at 37°C. Citrate blood was
diluted 1:1 with 0.9% sodium chloride and pre-warmed.
Aggregation to collagen, AA, and ADP was monitored
for 6 min. The results are reproducible with a variability
of <10%.
Endogenous estrogen
Sex was operationalized by circulating levels of estrogen
(17β-estradiol) in the female rabbits. Levels of 17β-estradiol
were collected immediately prior to embolization, and
analyses were performed by the University of California
San Diego Research Laboratory Services using the valid
and reliable Sorin kit (sensitivity = 5 pg/ml, s.e. 0.006 pg/ml,
r = 0.90 to direct assay) [21].
Power analysis
All power analyses were done using PASS 2008 version
08.0.6. Sample sizes were selected to provide 80% power
at a two-tailed significance level of 0.05 in two groups.
For platelet aggregation, assuming a large effect size ofestrogen based on the Loading of Aspirin and Clopido-
grel (LOAD) study (d = 0.80) [22], a sample size of 20
was required to detect a 20% difference between the
groups.
Statistical analysis
All statistical analyses were done using SPSS version
15.0 or later. A p value of <0.05 was considered signifi-
cant. Platelet aggregation inhibition was evaluated via a t
test analysis. A Spearman rank correlation was used to
examine the relationship of estrogen level and outcome
in female subjects. Variances are reported in standard
deviation.
Results
There were no statistically significant differences among
the subjects with respect to age, weight, surgical time, or
body temperature during surgery. 17β-estradiol levels in
the females ranged from 36.9 to 61.1 pg/ml (mean 44.1 ±
6.0 pg/ml). One subject died post-embolization but before
treatment and was replaced in the sample.
Inhibition of platelet aggregation
At all timepoints, platelet aggregation in response to col-
lagen, AA and ADP were not significantly different in fe-
males based on endogenous estrogen level (rs −0.31, p =
0.26). There were no significant differences in platelet
aggregation between historical male and current female
subjects (Table 2).
Estrogen
Although serum levels of endogenous estrogen in female
animals were not significantly associated with inhibition
of platelet aggregation at any timepoint or reagent, they
were significantly and positively associated with behav-
ioral outcome. Females with an RSCEM score of 0 (nor-
mal) had higher baseline endogenous estrogen levels as
compared to females with a score of 1 (abnormal score)
(46.5 pg/ml vs. 38.5 pg/ml, 95% CI 3.2–12.9, p = 0.003).
Higher estrogen levels were associated with higher P50 at
24 h (rs −0.70, p < 0.011) (Figure 1).
Discussion
Antiplatelet medications have been utilized in cardiac and
cerebrovascular occlusive diseases for primary prevention
of thrombotic events and secondary prevention of future
events [23-25]. The acute use of these medications con-
comitantly in large loading doses to acutely treat stroke
has only recently garnered empirical attention [22,26].
The purpose of this study was to assess for the mediating
effects of endogenous estrogen in female subjects on
stroke outcome after acute antiplatelet loading in the
RSCEM. In this pilot study of standard dose antiplatelet
loading after stroke, there was a significant, positive
Table 2 Stroke outcome measures by sex
Inhibition of platelet aggregation Male (historical comparison) Female p value
3 h
Collagen 33.2% (±12.2) 34.6% (±10.6) 0.53
AA 19.5% (±8.5) 22.7% (±15.1) 0.09
ADP 38.5% (±4.7) 37.5% (±6.6) 0.69
6 h
Collagen 65.1% (±10.1) 65.6% (±8.6) 0.78
AA 43.0% (±9.2) 42.7% (±7.7) 0.86
ADP 64.9% (±5.4) 66.8% (±7.4) 0.27
24 h
Collagen 71.1% (±11.6) 70.0% (±14.6) 0.51
AA 58.8% (±8.7) 56.6% (±5.8) 0.09
ADP 76.0% (±16.3) 74.4% (±9.6) 0.25
Inhibition of platelet aggregation was measured as change of impedance (Ω) in percentage from baseline platelet aggregation levels. Aggregation was measured
in reaction to collagen, arachidonic acid (AA), and adenosine diphosphate (ADP).
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neurologic outcomes in female rabbits. These neuropro-
tective effects appear to be hormone, rather than biologic
sex, mediated and support effects seen in other species.
Estrogen has been shown to have multiple neuroprotec-
tive effects in the literature. Neuroprotective effects include
(1) preservation of regional blood flow via amplification of
nitric oxide signaling and activation, (2) reduction of intra-
vascular leukocyte adhesion, and (3) anti-apoptotic activity
via caspase-mediated cell death [27]. Estrogen preserves re-
gional blood flow via endothelial vasodilatation due in part
to nitric oxide and prostanoid release, resulting in cerebro-
vascular dilatation, increased cerebral blood flow, and
decreased ischemic injury [28]. Estrogen has also been
shown to decrease leukocyte adhesion and inhibit theRSCE
le
veL
neg
ortsE
Figure 1 Estrogen and behavioral outcome. Females with an RSCEM sc
to females with a score of 1 (abnormal score) at 24 h (46.5 pg/ml vs. 38.5 p
significantly associated with higher P50 at 24 h (rs −0.70, p < 0.011).expression of adhesion molecules, thus minimizing the
pro-inflammatory damage [29,30]. Further studies of
antiplatelet medications in female models of stroke are
warranted to assess these processes.
Beyond neuroprotection, the correlation of estrogen
with a normal neurologic outcome seen in this study may
be related to its anti-apoptotic properties and its vascular
effects. Recent data suggest divergent pathways of ische-
mic cell death in females vs. males. Under conditions of
cerebral hypoxia, the neuronal tissue of males is more sus-
ceptible to poly(ADP-ribose) polymerase (PARP)-medi-
ated apoptosis than that of females [31]. Estrogen also
increases mitochondrial efficiency in the ischemic brain,
providing protection from caspase-mediated cell death via
the reduction of free radical production while stimulatingM 24 Hour
ore of 0 (normal) had significantly higher estrogen levels as compared
g/ml, 95% CI 3.2–12.9, p = 0.003). Higher estrogen levels were
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estrogen, with respect to stroke, may be its ability to cause
vasodilatation in the endothelium and increase blood flow
[35]. The ability to increase perfusion in the cerebral arter-
ies may provide tissue-sustaining perfusion to the brain tis-
sue at risk for hypoxic death. Though beyond the scope of
this study, it cannot be ruled out that standard antiplatelet
loading potentiates the anti-apoptotic and/or vascular ef-
fects of estrogen. While it is not hypothesized that estrogen
mediates or modifies the mechanism of action of either
clopidogrel or aspirin, the authors propose that there is a
synergistic effect of inhibiting platelet activity and providing
neuroprotection by both the medications and endogenous
estrogen leading to a decrease in ischemic damage. The
small sample size of females with higher 17-β-estradiol
levels did not allow for a statistically sound comparison
between the females with high estrogen levels and males in
this study. Future studies will include larger samples to
assess this effect.
While the administration of exogenous estrogen has
been extensively tested for its effect on stroke develop-
ment and outcome [36-40], limited work has been done
examining the role of endogenous estrogen in stroke
pathology and outcomes. Moreover, little clinical work
has addressed endogenous estrogen levels in stroke risk
or outcome [41,42]. This study aimed to correlate
endogenous estrogen levels and behavioral outcome in
post-pubescent, pre-menopausal female rabbits. Animal
(primarily rodent) and natural history studies show that
endogenous estrogen is protective in cerebral ischemia
[43,44]. Endogenous estrogen levels have been positively
correlated with increases in beneficial antioxidant
enzymes, decrease in lactate dehydrogenase (LDH) ac-
tivities, and decrease in leukocyte adhesion in the
ipsilateral hemisphere [40]. Future antiplatelet loading
studies in this model must examine these markers of
improved stroke outcome.
This study found that endogenous estrogen levels were
positively correlated with a normal neurologic outcome,
supporting the current literature's finding that higher
endogenous estrogen levels lead to smaller infarct
volumes [38]. Providing strong evidence for the role of
endogenous estrogen, several other studies have shown
that the neuroprotective effects of estrogen, described
above, can be abolished by ovariectomy [45-48] or by
declining estrogen levels during reproductive quiescence
resulting in effects that mimic male outcomes [49]. Fur-
ther testing must be done to compare stroke outcome in
pre-pubescent and post-menopausal rabbits in the medi-
ation of response to antiplatelet loading.
Limitations to this study exist. Estrogen level was not
manipulated in this study and showed only moderate
variance in the sample. This study was powered to re-
flect a large effect size for the variable of sex. It is likelythat the effect of sex may be either small or medium and
may require a larger sample size to elicit. In addition,
the lack of variance within this sample may have made it
more difficult to detect a significant difference in out-
come related to either very low or very high endogenous
levels. Subjects with ovariectomy or receiving estrogen
treatment must be studied to fully characterize its effect
on outcome. Another limitation was the use of young,
healthy rabbits. Future studies must be designed to
further explore the efficacy of acute antiplatelet therapy
and the role of endogenous estrogen and other sex ste-
roids in older animals with typical stroke co-morbidities.
This study did not employ a control group or dose-
escalation studies in the female subjects. Because this
was a pilot study, we were interested in comparing the
‘best dose’ of antiplatelet therapy in the female group as
a first step. Future studies will include a full comparison
of each group.
Despite compelling evidence for a neuroprotective role
of estrogen in cerebral ischemia, complete examination
of the relationship requires consideration of non-
estrogen-related physiological sex differences. Prospect-
ive studies of the role of exogenous and endogenous
progesterone, the androgens, and chromosomal differ-
ences are still required.
Conclusions
This is the first study to examine the mediating effects
of endogenous estrogen on stroke outcome in acute
antiplatelet loading treatment in a non-rodent species.
Trials focusing on sex and hormonal differences with all
stroke therapies must be explored to assess for differen-
tial benefits in men vs. women. It is vital that the role of
endogenous estrogen be explored with respect to novel
stroke therapies. Only this method of assessment will
allow researchers to glean an accurate assessment of the
independent effect of sex-related variables and the inter-
active effects of these variables with stroke treatment.
This research supports the further study of the effect of
endogenous estrogen levels on outcome with standard
dose antiplatelet loading in stroke patients not eligible
for revascularization therapies.
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